Amylin ve Glukoz Homeostazisi Üzerine Etkileri

Öz

Anahtar Kelimeler

• -

Amylin ve Glukoz Homeostazisi Üzerine Etkileri

Öz

Pankreatik bir hormon olan amylin gıda alımına cevap olarak insülinle birlikte pankreasın beta hücrelerinden salgılanır. Hayvanlarda yapılan bazı çalışmalar amylinin glukoz homeostazisi üzerine etkilerinin olduğunu ortaya koymuştur. Amylin mide boşalmasının kuvvetli bir inhibitörüdür. Bu etkiyi vagus siniri aracılığı ile yapmaktadır. Yapılan araştırmalarla arka beyinin area postrema bölgesinde amylin reseptörleri tanımlanmış ve amylinin mide boşalması üzerindeki etkilerinin bir kısmını merkezi sinir sistemi aracılığı ile gerçekleştirdiği ortaya koyulmuştur. Ayrıca amylin mide boşalması üzerine olan etkisinden farklı olarak gıda alımını da inhibe etmektedir. Buna ek olarak amylinin amino asitlerin uyardığı glukagon sekresyonunu da inhibe ederek gıda alımı sonrası endojen glukoz üretimini düşürebileceği de ortaya koyulmuştur. Bu derleme, yeni bir pankreatik hormon olan amylin ve glukoz homeostazisi üzerine etkileri konusunda bilgi vermek amacıyla hazırlanmıştır

Anahtar Kelimeler

• Amylin, insülin, pankreas, mide boşalması

Kaynakça

1. Ageev, A.K., 1986. Amyloidosis of the pancre- atic islets and diabetes mellitus. Arkh Patol., 48, 11-15.
2. Beaumont, K., Kenney, M.A., Young, A.A., Rink, T.J., 1993. High affinity amylin binding sites in rat brain. Mol Pharmacol., 44, 493-497.
3. Beeley N.R.A., Prickett K.S., 1996. The amylin, CGRP and calcitonin family of peptides. Expert Opin Ther Pat., 6, 555-567.
4. Bhavsar, S.P., Gedulin B.R., Beaumont, K., Rink T.J., Young A.A., 1995. Inhibition of gastric emptying and of food intake appear to be inde- pendently controlled in rodents. Proc aust Neuro- sci., 21, 460.
5. Bhavsar, S., Watkins, J., Young A., 1997. Com- parison of central and peripheral administration of amylin on reduction of food intake in rats. Diabetologia, A302.
6. Bhavsar, S., Watkins, J., Young, A., 1998. Syn- ergy between amylin and cholecystokinin for in- hibition of food intake in mice. Physiol Behav., 64, 557-561.
7. Bronsky, J., Prusa, R., 2003. Amylin fasting plasma levels are decreased in patients with os- teoporosis. Osteoporos Int., 15, 253-247.
8. Castle Arthur L, Kuo C.H., IVY J.L., 1997. Amylin influences insulin-stimulated glucose metabolism by two independent mechanism. En- docrinol Metab., 274, 6-12.

9. Chance, W.T., Balasubramaniam A., Zhang F.S., Wimalawansa S.J., Fischer J.E. 1991. Anorexia following the intrahypothalamic administration of amylin. Brain Res., 539, 352-354,.
10. Cooper, G.J., Willis, A.C., Clark, A., Turner, R.C., Sim, R.B., Reid, K.B., 1987. Putrification and characterization of a peptide from amiloid- rich pancreases of type 2 diabetic patients. P Natl Acad Sci USA., 84, 8628-8632.
11. Cooper, G.J.S., Leighton, B., Dimitriadis GD, Parry-Billings M, Kowalchuk, J.M., Howland, K., Rothbard, J.B., Willis, A.C., Reid K.B., 1988. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regu- lates glycogen metabolism in skeletal muscle. P Natl Acad Sci USA., 85, 7763-7766.
12. Cooper, M.E., Wookey, P.J., 1997. Amylin-its role in kidney. Nephrol dial transplant.,12, 8-10.
13. Fineman, M.S., Weyer, C., Maggs D.G., Strobel S., Kolterman O.G., 2002. The human amylin analog, pramlintide, reduces postprandial hyper- glucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res., 34, 504-508.
14. Frank, J.W., Saslow, S.B., Camilleri, M., Thom- forde, G.M., Dinneen, S.F., Rizza, R.A., 1995. Mechanisms of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology, 109, 755- 765.
15. Gedulın, B., Percy, A., Jodka, C., Young, A., 1997. Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion. Diabetologia, 40, A300.
16. Gerich, J.E., Schneider, V., Dippe, S.E., 1974. Characterization of the glucagon response to hy- poglycemia in man. J Clin Endocr Metab., 38, 77-82,
17. Gerich, J.E., 1993. Control of glycaemia. Best Pract Res Cl En., 7, 551-586.
18. Gren, G.M., Guan, D., Schwartz, J.G., Phillips, W.T., 1997. Accelerated gastric emptying of glu- cose in Zucker type 2 diabetic rats: role in post- prandial hyperglycaemia. Diabetologia, 40, 136- 142.
19. Guidobono F., 1998. Amylin and gastrointestinal activity. Genetic Pharmacol., 31, 173-177.
20. Hoppener, J.W., Nieuwenhuis, M.G., Vroom, T.M., Ahren, B.O., Lips, C.J., 2002. Role of islet amyloid in type 2 diabetes mellitus: consequence or cause. Mol Cel Endocrinol., 197, 205-212.
21. Koda J.E., Fineman, M., Rink, T.J., Dailey, G.E., Muchmore, D.B., Linarelli, L.G., 1992. Amylin concentrations and glucose control. Lancet, 339, 1179-1180.
22. Kruger, D.F., Gatcomb, P.M., Owen, S.K., 1999. Clinical implication of amylin and amylin defi- ciency. Diabetes, 25, 389-398.
23. Ludvik, B., Kautzky W.A., Prager, R., Thomaseth, K., Pacini, G., 1997. Amylin: history and overview. Diabetic Med., 14, 9-13.
24. Min, S.H., Farr, V.C., Lee, J., Prosser, C.G., Cooper, G.J.S., Davis, S.R., 1999. Metabolic ef- fects of amylin in lactating goats. J Anim Sci., 77, 1241-1248.
25. Moore C.X., Cooper, G.J.S., 1991. Co-secretion of amylin and insulin from cultured islet beta- cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Bioph Res Co., 179, 1-9.
26. Nakazato, M., Asai, J., Kangawa, K., Matsukura, S., Matsuo, H., 1989. Establishment of radioim- munoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem Bioph Res Co., 164, 394-399.
27. Ogawa, A., Harris, V., Mccorkle, S.K., Unger, R.H., Luskey, K.L., 1990. Amylin secretion from the rat pancreas and its selective loss after strep- tozotocin treatment. J Clin Invest., 85, 973-976.
28. Reda, T.K., Geliebter, A., Pı-Sunyer F.X., 2002. Amylin, food intake, and obesity. Obes Res., 10, 1087-1091.
29. Silvestre, R.A., Rodriguez-Gallardo, J., Jodka, C., Parkes, D.G., Pittner, R.A., Young, A.A., Marco, J., 2001. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Anim J Physiol Endocrinol Metab., 280, 443-449.
30. Tamura, T., Miyaura, C., Owan, I., Suda, T., 1992. Mechanism of action of amylin in bone. J Cell Physiol., 153, 6-14.
31. Unger, R.H., Orci, L., 1977. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med., 28, 119-130.
32. Van, R.D., Menard D.P., Fournier, A., St Pierre S, Quırıon R., 1994. Autoradiographic distribu- tion and receptor binding profile of [I-125]Bolton Hunter-rat amylin binding sites in the rat brain. J Pharmacol Exp Ther., 270, 779-787.
33. Westermark, P., Wilander, E., 1983. Islet amy- loid in type 2 non-insulin-dependent diabetes is related to insulin. Diabetologia, 24, 342-346.
34. Westermark, P., Wernstedt, C., Wilander, E., Sletten, K., 1986. A novel peptide in the calci- tonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun., 140, 827-831.
35. Wimalawansa, S.J., 1997. Amylin, calcitonin gene-related peptide, calcitonin, and adrenome- dullin: A peptide superfamily. Crit Rev Neuro- biol., 11, 167-239.
36. Young, A.A., Gedulin, B., Vine, W., Percy, A., Rink, T.J., 1995. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutane- ous injections of amylin. Diabetologia, 28, 642- 648.
37. Young, A.A., Gedulin, B.R., Rink, T.J., 1996. Dose-responses for the slowing of gastric empty- ing in a rodent model by glucagon like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabo- lism, 45, 1-3.
38. Young, A.A., Vine, W., Gedulin, B.R., 1996 Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Develop Res., 37, 231-248.
39. Young, A., 1997. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diab., 282-290.
40. Young, A., 1997. Role of amylin in nutrient in- take- animal studies. Diabetic Med., 14, 14-18.
41. Young, A., 2005. Historical background. Adv Pharmacol., 52, 1-18.